2 completed, 2 unknown. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Unknown 2 |
Follow PegBio Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy PB-201, PB-201 matched placebo, Metformin hydrochloride - Type 2 Diabetes Mellitus | Phase 3 | Unknown | PegBio Co., Ltd. | 546 | 2022-05-30 | 2022-04-22 |
| Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus PB-201, Vildagliptin, PB-201 matched placebo - Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Unknown | PegBio Co., Ltd. | 672 | 2021-09-30 | 2022-02-08 |
| Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy GLP-1 receptor agonist, Placebo - Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Completed | PegBio Co., Ltd. | 620 | 2020-06-23 | 2023-07-28 |
| Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects GLP-1 receptor agonist, Placebo - Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Completed | PegBio Co., Ltd. | 273 | 2020-04-27 | 2023-07-28 |
Lead-201 (2) · Metformin (1) · Vildagliptin (1)
China (4) · Hong Kong (1) · Taiwan (1)
Bin Gao, MD,PhD (1) · Bin Gao, MD，PhD (1) · Guixia Wang, MD,PhD (1) · Hui Liu, MD，PhD (1) · HuiMin Zhou, MD，PhD (1) · Huige Shao, MD,PhD (1) · Huige Shao, MD，PhD (1) · Jianhua Ma, MD,PhD (1) · Jianhua Ma, MD，PhD (1) · Jiarui Li, MD,PhD (1) · Jing Yang, MD,PhD (1) · Jing Yang, MD，PhD (1) · Jingna Lin, MD,PhD (1) · Jingna Lin, MD，PhD (1) · Lan Xu, MD，PhD (1)